title: Bradykinin antagonists reduce leukocyte-endothelium interactions after global cerebral ischemia.
abstract: The aim of the present study was to evaluate the influence of bradykinin on microcirculatory changes and outcome after global cerebral ischemia (15 minute) in Mongolian gerbils. The cerebral microcirculation was investigated by fluorescent intravital microscopy. Survival and functional outcome was evaluated up to 4 d after ischemia. Animals were treated with the selective B(1) and B(2) receptor antagonists B 9858 and CP 0597, respectively, and the nonselective B(1)/B(2) receptor antagonist B 9430. Leukocyte activation was significantly reduced by all antagonists as indicated by a significant decrease in the number of rolling (33 +/- 20, 6 +/- 8, 9 +/- 10, and 13 +/- 10) and adherent leukocytes (9 +/- 7, 3 +/- 4, 1 +/- 1, and 2 +/- 3. 100 microm(-1) x min(-1) in controls and in animals treated with B(1), B(2), and B(1)/B(2) antagonist, respectively). Arteriolar diameters were significantly reduced during reperfusion (35 +/- 11 before and 27 +/- 8 microm 40 minutes after ischemia) in animals treated with the B(2) antagonist. The postischemic hypoperfusion, however, was not affected. Mortality was significantly higher in animals treated with the B(1) and the B(1)/B(2) antagonist. The authors concluded that bradykinin is involved in postischemic disturbances of cerebral microcirculation. The therapeutic effect of specific bradykinin receptor antagonists on functional outcome, however, remains unclear.
authors.affiliation: Department of Neurosurgery, Albert-Ludwigs-University, Freiburg i.B., Germany. lehmberg@nz.ukl.uni-feiburg.de
authors.forename: Jens
authors.initials: J
authors.lastname: Lehmberg
authors.forename: Jürgen
authors.initials: J
authors.lastname: Beck
authors.forename: Alexander
authors.initials: A
authors.lastname: Baethmann
authors.forename: Eberhard
authors.initials: E
authors.lastname: Uhl
mesh_terms: D000818:Animals; D001794:Blood Pressure; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D002450:Cell Communication / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000166:cytology*; D005849:Gerbillinae; D007962:Leukocytes / Q000166:cytology*; D008833:Microcirculation / Q000187:drug effects; D009842:Oligopeptides / Q000494:pharmacology; D010841:Pia Mater / Q000098:blood supply; D015427:Reperfusion Injury / Q000188:drug therapy / Q000473:pathology
chemical_list: C121350:B 9858; C107323:CP 0597; D009842:Oligopeptides; D001920:Bradykinin